ArticleYonsei medical journal2024

Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma.

Hong Jun Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.